Skip to main content
Clinical Trials/ACTRN12609000904279
ACTRN12609000904279
Recruiting
Phase 2

Study of molecular changes induced by treatment with bevacizumab in metastatic breast cancer

Georgios Kesisis0 sites40 target enrollmentOctober 19, 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
metastatic breast cancer
Sponsor
Georgios Kesisis
Enrollment
40
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 19, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Georgios Kesisis

Eligibility Criteria

Inclusion Criteria

  • histologically proven metastatic breast cancer, locally accessible disease (breast tumor, skin mets, lymph node mets), Performance status (PS) 0\-1, normal liver and kidney function

Exclusion Criteria

  • history of thrombotic disease, uncontrolled brain metastases, pregnancy, lactation, prior bevacizumab exposure, recent surgery (within 4 weeks), active bleeding, active infection, unhealed wound, use of anticoagulants in therapeutic doses

Outcomes

Primary Outcomes

Not specified

Similar Trials